Enhabit, Inc. (NYSE:EHAB – Get Rating) has received an average rating of "Hold" from the eight ratings firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $16.43.

EHAB has been the subject of a number of analyst reports. Stifel Nicolaus initiated coverage on shares of Enhabit in a report on Monday, December 5th. They set a "buy" rating and a $17.00 target price for the company. UBS Group began coverage on shares of Enhabit in a report on Thursday, December 8th. They issued a "sell" rating and a $12.00 price objective for the company. Oppenheimer began coverage on Enhabit in a research report on Thursday, October 13th. They set a "market perform" rating on the stock. CJS Securities began coverage on Enhabit in a research note on Tuesday, December 13th. They issued a "market perform" rating and a $18.00 target price for the company. Finally, Credit Suisse Group lowered their target price on Enhabit from $19.00 to $15.00 and set a "neutral" rating for the company in a research note on Friday, November 4th.

Enhabit Trading Down 1.6 %

Enhabit stock opened at $12.69 on Friday. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.63. The business's 50-day moving average price is $13.26. Enhabit has a 1-year low of $11.65 and a 1-year high of $25.25.

Insider Activity

In related news, Director Jeffrey Bolton acquired 2,000 shares of the stock in a transaction on Wednesday, November 9th. The stock was acquired at an average price of $12.75 per share, for a total transaction of $25,500.00. Following the completion of the purchase, the director now owns 14,597 shares of the company's stock, valued at $186,111.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Gregory S. Rush acquired 8,300 shares of the stock in a transaction on Monday, November 7th. The stock was acquired at an average price of $12.69 per share, for a total transaction of $105,327.00. Following the completion of the purchase, the director now owns 16,597 shares of the company's stock, valued at $210,615.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey Bolton acquired 2,000 shares of the stock in a transaction on Wednesday, November 9th. The shares were bought at an average price of $12.75 per share, with a total value of $25,500.00. Following the purchase, the director now directly owns 14,597 shares of the company's stock, valued at approximately $186,111.75. The disclosure for this purchase can be found here. Insiders bought a total of 13,000 shares of company stock worth $164,903 in the last quarter.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Strs Ohio bought a new stake in shares of Enhabit in the 2nd quarter worth $3,262,000. OLD Mission Capital LLC bought a new stake in shares of Enhabit in the 2nd quarter worth $379,000. CI Investments Inc. bought a new stake in shares of Enhabit in the 2nd quarter worth $27,000. Northern Trust Corp bought a new stake in shares of Enhabit in the 2nd quarter worth $494,000. Finally, Millennium Management LLC bought a new stake in shares of Enhabit in the 2nd quarter worth $230,000. Hedge funds and other institutional investors own 95.55% of the company's stock.

About Enhabit

(Get Rating)

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.

Featured Articles

• Get a free copy of the StockNews.com research report on Enhabit (EHAB)
• Can Chip Gear Maker Lam Continue Its Rally As Earnings Slow?
• Bed Bath & Beyond Stock Crumbles 24% On Possible Bankruptcy News
• Why Is Kraft Heinz Moving Higher
• What will this mean for the Devon Energy stock price this year?
• Nio Stock, Is This The Bottom ?

Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.